Olema Pharmaceuticals (OLMA) News
Filter OLMA News Items
OLMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OLMA News Highlights
- For OLMA, its 30 day story count is now at 6.
- Over the past 22 days, the trend for OLMA's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ARCH are the most mentioned tickers in articles about OLMA.
Latest OLMA News From Around the Web
Below are the latest news stories about Olema Pharmaceuticals Inc that investors may wish to consider to help them evaluate OLMA as an investment opportunity.
Olema Oncology to Present at Cowen 42nd Annual Health Care ConferenceSAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 2:50 p.m. ET (11:50 a.m. PT). A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be arch |
We're Hopeful That Olema Pharmaceuticals (NASDAQ:OLMA) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Olema reports inducement grants of 270K stock optionsOlema Pharmaceuticals (OLMA) granted stock options to two new employees to buy a total 270K common shares under the company''s 2022 Inducement Plan.The company''s new Chief Medical |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 270,000 shares of the Company's common stock, effective as of February 1, 2022. An option to purchase 250,000 sh |
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema’s Scientific Advisory Board SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerci |
Our Take On Olema PharmaceuticalsNo summary available. |
Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare ConferenceSAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET (2:15 p.m. PT). A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will |
Tybourne Capital Management (hk) Ltd Buys Snowflake Inc, Pinduoduo Inc, KE Holdings Inc, Sells ...Investment company Tybourne Capital Management (hk) Ltd (Current Portfolio) buys Snowflake Inc, Pinduoduo Inc, KE Holdings Inc, Block Inc, StoneCo, sells Peloton Interactive Inc, S&P Global Inc, Bill.com Holdings Inc, PayPal Holdings Inc, Amazon.com Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Tybourne Capital Management (hk) Ltd. |
Jefferies Maintains Their Buy Rating on Olema Pharmaceuticals (OLMA)Jefferies analyst Michael Yee maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) yesterday and set a price target of $18.00. The company's shares closed last Monday at $10.31, close to its 52-week low of $8.25. According to TipRanks.com, Yee is a 3-star analyst with an average return of 2.3% and a 43.2% success rate. Yee covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Vertex Pharmaceuticals, and Allogene Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Olema Pharmaceuticals with a $32.50 average price target, a 215.2% upside from current levels. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe've reached the halfway point of the week and there's no slowing down as we dive into the biggest pre-market stock movers for Wednesday! |